Computerized Thermal Imaging Announces Favorable Ruling on Appeal

Computerized Thermal Imaging Announces Favorable Ruling on Appeal
Ninth Circuit Upholds Lower Court Decision 


OGDEN, Utah, Aug. 31  /PRNewswire-FirstCall/ -- Computerized Thermal Imaging,
Inc. ("CTI") (OTC:COIB) (BULLETIN BOARD: COIB)  today announced that the United
States Court of Appeals for the Ninth Circuit has ruled in CTI's favor in the
appeal of the United States District Court decision to dismiss the plaintiffs'
claims in the proceeding entitled "In re: Computerized Thermal Imaging, Inc.,
Securities Litigation."  The Ninth Circuit decision upheld the determination of
the District Court to dismiss the plaintiff's complaint because it failed to
adequately plead a case.

"We have always been confident that the appellate court would rule in our
favor," commented Richard V. Secord, Chairman of the Board and CEO of
Computerized Thermal Imaging.  "We are very pleased to put this matter behind
us and focus our resources on moving our BSC 2100 infrared cancer detection
device into Canada and promoting our TIP system and Photonic Stimulator.  We
continue to pursue FDA approval for the BCS 2100 in the United States and hope
to enter the U.S. market as soon as the FDA approves the BSC 2100 device.
Meanwhile, the TIP system and Photonic Stimulator continue to be sold
throughout the states as well as Canada and China."

About CTI

CTI designs, manufactures and markets thermal imaging and infrared devices and
services used for clinical diagnosis, pain management and non-destructive
testing of industrial products and materials.  CTI has developed six
significant proprietary technologies, four of which relate to its breast
imaging system, BCS 2100.  These include a climate-controlled examination unit
to provide patient comfort and facilitate reproducible tests for the BCS 2100;
an imaging protocol designed to produce consistent results for the BCS 2100; a
statistical model that detects physiological irregularities for the BCS 2100,
and infrared imaging and analysis hardware, including a proprietary
heat-sensing camera.  CTI also markets the Thermal Image Processor and Photonic
Stimulator, two cleared pain management devices used for diagnostic imaging and
therapeutic treatment.

This press release contains "forward-looking statements" within the meaning of
Section 27A of the Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended.  These forward-looking statements
are subject to certain risks, trends and uncertainties that could cause actual
results to differ materially from those projected.  Among those risks, trends
and uncertainties are CTI's pending application before the FDA seeking
pre-market approval of CTI's BCS 2100 breast imaging system, CTI's ability to
raise additional capital to fund cash requirements for future operations and
CTI's ability to continue as a going concern.  In particular, careful
consideration should be given to cautionary statements made in the various
reports CTI has filed with the Securities and Exchange Commission. CTI
undertakes no duty to update or revise these forward-looking statements. 

DATASOURCE: Computerized Thermal Imaging, Inc.



CONTACT:  BJ Mendenhall of Computerized Thermal Imaging, Inc.,

[phone], ext. 31

Copyright